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Immunotherapya b s t r a c t
Undifferentiated embryonal sarcoma of the liver (UESL) is a rare malignant tumor that occurs predomi-
nantly in children and has a poor prognosis. Here, we report a novel case in which the UESL presented in
the left lobe of the liver and metastasized into both lungs after surgical resection. The patient recovered
after our administration of an immunotherapeutic combination of DCs (Dendritic Cells) and multi-
immune cells, such as cytokine-induced killer cells (CIKs) and natural killer cells (NKs). After the third
cycle of immunotherapy, a CT scan showed a remarkable regression of the lung metastases. This ﬁnding
supports the conclusion that the DC-based treatment is a promising potential strategy for treating
patients with relapsed UESL.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Undifferentiated embryonal sarcoma of the liver (UESL), also
known as undifferentiated liver sarcoma (USL), is the most com-
mon malignant mesenchymal tumor of the liver in children aged
6–10 years [1]. A poor prognosis is associated with UESL due to
its high malignancy and frequent metastasis to other parts of the
body, such as the lung, peritoneum and pleura [2]. Although the
treatment of primary liver sarcomas includes surgery, radiotherapy
and chemotherapy, the optimal treatment of patients with meta-
static sarcoma remains controversial [3]. Some cases have shown
that comprehensive therapeutic tactics that combine chemother-
apy with other feasible options is the most beneﬁcial treatment
strategy [4]. Meanwhile, immunotherapy has also been shown to
play an important role in the treatment of this cancer [5]. Su and
his team have shown that the prognosis of subjects with metastatic
renal cell carcinoma was signiﬁcantly improved upon the adminis-
tration of CIKs [6]. Moreover, the infusion of HCC patients with
anti-CD3 and IL-2 stimulated autologous T lymphocytes and was
able to markedly boost post-surgical recurrence-free survival [7].
These pioneering works have paved the way for the application
of cellular immunotherapy for other cancers.Here, we report a case of UESL with lung metastasis in which we
have achieved a good result using immunotherapy. In this case,
metastatic lesions were spread sparsely throughout both lungs,
as determined by CT, following the surgery for a left hemihepatec-
tomy. The autologous tumor lysate-pulsed DC vaccines with multi-
immune cells (CIK, NK) were administered to the patient, and a
partial response (PR) was achieved following the ﬁrst cycle. After
the third cycle, the regressions were re-examined, and the patient
showed stable disease.
2. Materials and methods
2.1. Cell culture
The patient underwent leukapheresis through a blood separator
(Fresenius Kabi, COM.TEC). PBMCs were collected through centri-
fugation with Ficoll-Hypaque (PAA) and were aliquoted into four
portions for the corresponding preparations of the DC vaccine
and the CIK, cdT, and NK cells.
2.1.1. DC cells
DCs were prepared as previously described [8]. Brieﬂy, PBMCs
were cultured with X-VIVO 15 (Lonza) for 2 h at 37 C in a 5%
CO2 air incubator. Non-adherent cells were removed and cultured
at 37 C in a 5% CO2 air incubator for 8 days in X-VIVO15 contain-
ing GM-CSF (500 U/ml; Peprotech Inc., US) and IL-4 (10 ng/ml;
Table 1
The infusion protocol for one cycle of treatment.
DC vaccine and immune cells Injection date (day) Injection
DC1, DC2, DC3, DC4 8, 8, 15, 22 i.v., i.d., i.d., i.d.
CIK1, CIK2, CIK3, CIK4 10, 11, 12, 13 i.v., i.v., i.v
NK1, NK2 14, 15 i.v., i.v
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hepatocellular tumor lysate was added to pulse the DCs for 24 h.
Then, the cells were cultured in media supplemented with
500 U/ml of tumor necrosis factor alpha (TNF-A; Peprotech Inc.,
USA) for an additional 48 h, and the cells were then harvested for
the subsequent preparations.
2.1.2. CIK cells
CIKs were prepared as previously described [9]. Brieﬂy, non-
adherent PBMCs were prepared and grown in GT-T551 (Takara Bio-
Inc) containing human interferon c (IFN-c, 1000 U/ml, Takara Bio-
Inc) at 37 C, 5% CO2 for 24 h. Then, 100 ng/ml of a monoclonal
antibody against CD3 (R&D), 300 IU/ml IL-2 (1000 U/ml; SL
PHARM, CN) and 1000 U/ml IL-1a (Takara BioInc) were added.
Media containing IL-2 were added at 1- or 2-day intervals. The cells
were harvested between days 11 and 14.
2.1.3. NK cells
PBMCs were cultured in NK culture media and harvested
between days 12 and 15.
2.2. Treatment plan
The treatment procedure is presented in Table 1. Each cycle
included the administration of four DC vaccines, three infusions
of CD3AKs and CIKs, and 2 infusions of NKs. The DCs were given
intravenously (i.v.) at ﬁrst and then intradermally (i.d.) every week
three additional times. The immune cells were all given i.v.
The patient received six cycles of DC-based treatment from
October 30, 2011 to March 8, 2013. For the ﬁrst three-cycles, three
doses of the infusions were administered at 45-day intervals. The
fourth dose was administered 3 months after the third dose, andFig. 1. The patient status before the DC-based treatment. The appraisal included compu
mass in the left hepatic lobe by CT. Panel (B) shows highly atypical spindle cells and giathe interval between the remaining three cycles was extended to
5 months. During the course of the clinical practice, the progres-
sion of the UESL was monitored by chest CT.3. Results
3.1. Clinical evaluation of the patient
A 9-year-old boy hospitalized in the Chinese Armed Police Gen-
eral Shan Dong Hospital had an 11-day history of intermittent
fever in September 2011. The abdominal computed tomography
(CT) showed a 15  16  10 cm well-circumscribed hypodense
lesion in the left lobe of the liver, and this lesion showed non-
homogeneous enhancement after the administration of nitro-arte-
rial contrast. The lesion possessed a non-homogeneous density,
and irregular necrosis was identiﬁed within the lesion (Fig. 1A).
The tests for hepatitis and for the detection of tumor markers were
negative. The patient was diagnosed with undifferentiated embry-
onal sarcoma of the liver (UESL), and he underwent a left hemihep-
atectomy to remove the lesion on September 23, 2011. During the
surgery, the lesion was observed in the left lobe of the liver with a
size of 15  15  14 cm and had invaded into the liver capsule.
After the surgery, both histological analysis and immunohisto-
chemistry examinations showed several malignant neoplasms thatted tomography for his liver and lungs and a tumor biopsy. Panel (A) shows a huge
nt cells in the tumor. Panel (C) shows the lung metastases by CT.
Fig. 2. Expansion of CIK and NK cells from autologous PBMCs ex vivo.
Table 2
The percentages of lymphocyte subsets in the peripheral blood before and after
treatment.
Time CD3+ (%) CD4+ (%) CD8+ (%) CD56+ (%)
Pre-treatment 58.31 ± 6.81 34.28 ± 6.25 24.56 ± 5.16 4.86 ± 0.59
Post-treatment 69.92 ± 3.47 47.52 ± 5.24 27.84 ± 4.70 16.63 ± 1.19
S. Xie et al. / Cellular Immunology 290 (2014) 185–189 187are characteristic of UESL (Fig. 1B). Moreover, massive necrosis and
cancer-associated thrombosis were found in vas. Immunohisto-
chemistry analysis showed that the tumor cells expressed vimen-
tin and a-AT, and some cells also expressed HMB45 and MPO.
Moreover, the tumor cells were negative for CK, SMA, desmin,
CD34 and AFP. According to ﬁndings from a comprehensive set of
tests, the ﬁnal diagnosis was UESL.
After the surgery, the patient recovered well and received no
further treatment. However, metastatic niduses in both lungs were
identiﬁed by chest CT on October 3, 2011. Multiple roundish
hyperdense shadows (variable in size) were observed in both
lungs, and one section was up to 1.5 cm in diameter (Fig. 1C).3.2. Expansion
The expansion of CIK and NK cells from PBMCs using ex vivo
technique is shown in Fig. 2. (Due to their non-proliferation, DC
data are not shown).3.3. FACS staining
The DC cells were harvested and phenotypically characterized
by ﬂow cytometry, and the results showed that the DCs had a
mature DC phenotype, as they were CD83+ and CD86+ (Supple-
mentary Fig. 1A). The number of cells that were CD3-CD56+ (NK
surface markers) was expanded (Supplementary Fig. 1B), andFig. 3. Clinical response to the DC-based treatment. (A) one moCD3+ and CD56+ were preferentially expressed by the CIK cells
(Supplementary Fig. 1C).3.4. Treatment
The patient received six cycles of an immunotherapy that com-
bined the DC vaccine with multi-immune cells (CIK, NK). The clin-
ical response presented in Fig. 3 shows signiﬁcant regression of
multiple metastatic sites after the 1st cycle, and these lesions
had nearly vanished after the third treatment cycle.3.5. Clinical response
3.5.1. Curative effects
The clinical responses to our treatments were evaluated accord-
ing to the Response Evaluation Criteria in Solid Tumors (RECIST)
criteria [10]. One month after the 1st cycle, CT showed that the
lesions were signiﬁcantly reduced and that the response could be
deﬁned as PR according to the RECIST criteria (Fig. 3A). One month
after the 3rd cycle, CT revealed that the lesions had almost disap-
peared from both lungs (Fig. 3B). Re-examination after the 5th
cycle showed no further progression.3.5.2. Immune response
To assess the immune response, the levels of CD3+, CD8+ and
CD56+ in the serum were determined before and after the treat-
ment using ﬂow cytometry (Table 2). The result showed a signiﬁ-
cant increase in the expression of CD3+ and CD4+, and the
expression of CD8+ was also slightly up-regulated.
To assess the in vivo reactivity toward the infusion, delayed-
type hypersensitivity (DTH) tests were conducted i.d. before the
DC-based treatment and one week after each round of treatment.
A positive DTH response was deﬁned as a redness spot >5 mm in
mean diameter at 48 h after injection [13]. In this case, the DTH
tests were negative before the treatments were initiated. After
the 1st cycle, the test became positive and remained so for the fol-
lowing cycles.nth after the 1st cycle. (B) one month after the 3rd cycle.
188 S. Xie et al. / Cellular Immunology 290 (2014) 185–1894. Discussion
Undifferentiated embryonal sarcoma of the liver (UESL) is a
rare, rapidly growing malignant spindle cell tumor [3]. UESL
accounts for 9–15% of all hepatic tumors in children. However, it
is a rare disease, given that a mere 200 cases have been reported
[11]. It predominantly occurs in children that are 5- to 10-years-
old without sex predilection [12,13]. The tumor is most often
found in the right lobe of the liver and is characterized by a clear
boundary, hemorrhaging, necrosis and cystic degeneration [14].
The clinical symptoms include an abdominal mass, pain, mild fever
and, rarely, jaundice. In this study, we have presented a case of a 9-
year-old boy with UESL. It should be noted that the lesion was
observed in the left lobe of the liver, which is rare among the
recorded cases of UESL.
UESL is a malignant neoplasm with poor prognosis, and the
overall survival is often less than 1 year due to recurrence or
metastasis [15]. Surgery is thought to be the only way to com-
pletely cure the disease. However, only 65% of patients are candi-
dates for surgical resection. According to the existing clinical
studies, the risk of recurrence after surgery is relatively high in
the ﬁrst 2 years. In our case, the cancer reoccurred in the lungs a
mere half-month after surgery. Because the patient was not a can-
didate for chemotherapy or radiotherapy after surgery, we chose
an immunotherapeutic strategy that is based on an autologous
tumor lysate-pulsed DC vaccine combined with CIKs and NKs.
Immunotherapy for primary hepatic carcinoma has become a
new option for treating cancer and is able to shrink lesions and
prevent recurrence [5]. It targets and kills cancer cells by inducing
or boosting the existing tumor-speciﬁc immune response. Peng
et al. performed a clinical trial for a hepatic carcinoma vaccine,
and they found that the recurrence rate declined signiﬁcantly in
the tumor vaccine cohort (1 year, 12.6%; 2 years, 35.9%; 3 years,
54%) compared with the control. They also found that the DTH
response-positive patients had a recurrence rate lower than that
for those negative for the DTH response [16]. In 2005, Lee et al.
conﬁrmed the curative effect of a DC vaccine pulsed with autolo-
gous tumor lysate in patients with HCC. There were 31 patients
enrolled in the study, and 14 patients achieved a partial response;
the remaining patients experienced clear stabilization of the dis-
ease. Furthermore, the 1-year survival was remarkably improved
[17]. These ﬁndings demonstrate that immunotherapy can be
effective against a variety of cancers. DCs, the most effective anti-
gen-presenting cells, have been applied in cellular immunotherapy
research around the world [18]. Since the ﬁrst DC vaccine for pros-
tate cancer was approved by the FDA, DC-based immunotherapy
has become an increasingly promising new therapeutic option.
Much research has been conducted with the goal of improving
the efﬁcacy of DC-based immunotherapy; these studies have
investigated the use of DCs loaded with tumor-speciﬁc lysate,
diverse cytokine cocktails, and the development of co-culture tech-
niques with other immune cells.
CIKs are well known for their antitumor activity. Pei Zhou and
his team demonstrated that a DC vaccine combined with CIK cells
induced a T-cell-mediated immune response that included activat-
ing native T cells, which played a critical role in the innate and
adaptive immune responses [19]. NK cells are naturally cytotoxic
and exert their adaptive antitumor activity by interwinding with
other immune cells. NK cells and DCs are closely connected. NK
cells activated by DCs contribute to the development of potent
innate immunity. Intriguingly, activated NK cells also fuel the DC
maturation process, including activation, maturation, and cytokine
production, and promote adaptive immunity [20]. Therefore, we
combined an autologous tumor lysate-loaded DC vaccine with
NK and CIK cells with the goal of effectively activating the innate
and adaptive immunity antitumoral effects.In this case, the patient had partial response after the ﬁrst round
of the treatment, and his lesions had almost disappeared after the
third round. Later on, the patient showed stable disease, and there
were no severe adverse effects. In the following 25 months, the
patient experienced a clear stabilization of his disease, which is
extremely rare for those suffering from a recurrence of UESL. It
has been reported that patients with HCC have severe immunosup-
pression, and this might be associated with the proportion of T cell
subpopulations. Compared with the average level, the ratio of CD3,
of CD4 and of CD4/CD8 T cells diminished, whereas that of CD8
cells increased. Moreover, the NK activity of HCC patients
decreased [21]. Our DC-based treatment with a DC vaccine loaded
with autologous tumor lysate in combination with CIKs and NKs
certainly affected the proportion of CD3, CD4, and CD8, and thus,
the CD4/CD8 ratio was restored to the normal level. In addition
to the pulsed DC vaccine-based strategy, we attempted to enhance
the NK activity of the UESL patient using an infusion of ex vivo
expanded NK cells. In agreement with Holtl L’s work [22], this
treatment was successful, suggesting that the autologous tumor
lysate-pulsed DCs were involved in the beneﬁcial effects. The
details of the underlying mechanism require further investigation.
In this case, most of DC vaccines were injected i.d. According to
previous studies, i.d. administration was attractive because it likely
targets immature DCs to secondary lymphoid organs, especially
the draining lymph nodes where, upon maturation/activation
(increased expression of major histocompatibility complex and
the co-stimulatory molecules (CD86+, CD80+, CD40+)), DCs can
prime T lymphocytes. [23]. Evidently, this method of administra-
tion is superior to intravascular.
The patient’s immune reactivity was assessed by DTH and
immune function analysis. The results showed that repeated treat-
ments elicited an increment in the immune response, and the
patient’s disease stabilized. Thus, immunotherapy may be a prom-
ising treatment plan for the recurrence of UESL, and any remaining
skepticism should be resolved by more substantial evidence.
In conclusion, we employed an immunotherapeutic strategy to
treat a patient with UESL that combined an autologous tumor
lysate-loaded DC vaccine with CIK and NK cells. To our knowledge,
this is the ﬁrst time that immunotherapy has been used to treat
UESL. Our clinical outcome was PR after the ﬁrst round of the treat-
ment, and SD was reached following the third round with no
severe adverse effects. The use of immunotherapy to treat patients
with a recurrence of UESL may be feasible and well tolerated. Fur-
ther studies are necessary to deﬁne the clinical efﬁcacy.Acknowledgments
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